Shrinkage in nonlinear mixed-effects population models: Quantification, influencing factors, and impact

AAPS Journal

Volumn 14, Issue 4, 2012, Pages 927-936

  Xu, Xu Steven ^a   Yuan, Min ^b   Karlsson, Mats O ^c   Dunne, Adrian ^a   Nandy, Partha ^a   Vermeulen, An ^d  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c UPPSALA UNIVERSITY   (Sweden)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Empirical Bayes estimate; Mixed effects models; Population PK PD; Shrinkage

Indexed keywords

ANALYTICAL ERROR; ARTICLE; BAYES THEOREM; COMPARTMENT MODEL; MATHEMATICAL MODEL; MONTE CARLO METHOD; POPULATION MODEL; QUANTITATIVE ANALYSIS;

BAYES THEOREM; DRUG DESIGN; HUMANS; LINEAR MODELS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD; NONLINEAR DYNAMICS; PHARMACOKINETICS; SAMPLE SIZE;

EID: 84869121395     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9407-9     Document Type: Article

References (38)

1. Kloft C, Poggesi I. Current and future directions of pharmacokinetic and pharmacokinetic-pharmacodynamic modelling and simulation: population approach group in Europe 19th annual meeting. Expert Opin Drug Metab Toxicol. 2010;6(12):1599-604.
2. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963-74.
3. Sheiner L, Wakefield J. Population modelling in drug development. Stat Methods Med Res. 1999;8(3):183-93.
4. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558-69.
5. Fitzmaurice GM. Longitudinal data analysis. Boca Raton: Chapman & Hall; 2008.
6. Carlin BP, Louis TA. Bayesian methods for data analysis. 3rd ed. Boca Raton: CRC Press; 2009.
7. Carlin BP, Louis TA. Bayes and empirical Bayes methods for data analysis. 2nd ed. Boca Raton: Chapman & Hall; 2000.
8. Strenio JF, Weisberg HI, Bryk AS. Empirical Bayes estimation of individual growth-curve parameters and their relationship to covariates. Biometrics. 1983;39(1):71-86.
9. Louis TA. Estimating a population of parameter values using Bayes and empirical Bayes methods. J Am Stat Assoc. 1984;79:393-8.
10. Ghosh M. Constrained Bayes estimation with applications. J Am Stat Assoc. 1992;87:533-40.
11. Efron B, Morris C. Limiting the risk of Bayes and empirical Bayes estimators-part I: the Bayes case. J Am Stat Assoc. 1971;66:807-15.
12. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17-20.
13. Bertrand J, Comets E, Laffont CM, Chenel M, Mentre F. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. J Pharmacokinet Pharmacodyn. 2009;36(4):317-39.
14. INRIA (Institut National de la Recherche en Informatique et Automatique). Monolix 4.0.1 user Guide (http://www.lixoft.net/wp-content/uploads/2011/10/ Monolix4-UserGuide1.pdf); 2011.
15. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. Hoboken: Wiley-Interscience; 2004.
16. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2000.
17. Bonate PL, SpringerLink (Online service). Pharmacokinetic-pharmacodynamic modeling and simulation. In. Boston, MA: Springer Science + Business Media, Inc.; 2006.
18. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1983;11(3):303-19.
19. Sheiner BL, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm. 1981;9(5):635-51.
20. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8(6):553-71.
21. Vonesh EF. A note on the use of Laplace's approximation for non-linear mixed-effects models. Biometrika. 1996;83:447-52.
22. Wolfinger RD. Laplace's approximation for non-linear mixed models. Biometrika. 1993;80:791-5.
23. Wolfinger RD, Lin X. Two Taylor-series approximation methods for nonlinear mixed models. Comput Stat Data Anal. 1997;25 (4):465-90.
24. Lindstrom ML, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics. 1990;46(3):673-87.
25. Davidian M, Giltinan DM. Nonlinear models for repeated measurement data. 1st ed. London: Chapman & Hall; 1995.
26. Pinheiro JC, Bates DM, ebrary Inc. Mixed-effects models in S and S-PLUS. New York: Springer; 2000.
27. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit-A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-57.
28. Bauer RJ. Nonmem users guide: introduction to Nonmem 7. Ellicott City: ICON Development Solutions; 2010.
29. Pfanzagl J, Hamböker R. Parametric statistical theory. W. de Gruyter, Berlin 1994.
30. van der Vaart HR. Some extensions of the idea of bias. Ann Math Stat. 1961;32(2):436-47.
31. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503-12.
32. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996;24(2):153-72.
33. Searle SR, Casella G, McCulloch CE. Variance components. New York: Wiley; 1992.
34. Savic R, Wilkins JJ, Karlsson MO. (Un)informativeness of empirical Bayes estimate-based diagnostics [abstr T3360]. AAPS J. 2006 8(S2).
35. Lacroix BD, Friberg LE, Karlsson MO. Evaluating the IPPSE method for PKPD analysis [Abstr 1843]. PAGE 2010;19: .
36. Wade JR, Karlsson MO. Combining PK and PD data during population PK/PD analysis [Abstr 139]. PAGE 1999;8: .
37. Lyles RH, Xu J. Classifying individuals based on predictors of random effects. Multicenter AIDS Cohort Study. Stat Med. 1999;18(1):35-52.
38. Davidian M, Gallant AR. Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine. J Pharmacokinet Biopharm. 1992;20 (5):529-56.